Introduction to innate immunity
Epithelial and mucosal tissues, including those lining the lung and gut, function as a physical barrier against pathogens [1, 2] . However, when this physical barrier is disrupted, pathogens are rapidly detected by cell surface pathogen-recognition receptors (PRRs), representing an essential step in the initiation of innate immune responses [3-6].
Pathogen-recognition receptors, including Toll-like receptors (TLRs), retinoic acid-inducible gene I (RIG-I)-like receptors and Nod-like receptors [7] , bind distinct microbial components to ensure a tailored response of the host immune system to the pathogen. As such, PRR engagement leads to the activation of highly coordinated downstream signalling resulting in the production of
Introduction to microRNAs

Biogenesis of microRNAs
MicroRNAs (miRNAs) are 19-25 nucleotide (nt) long endogenous noncoding RNAs involved in the control of messenger RNA stability and translation. They were first discovered in 1993 by Ambros and colleagues, revolutionizing prior conceptions of mRNA translation [11] . The canonical miRNA processing starts with the transcription of a miRNA gene, typically by RNA polymerase II, into a primary-miRNA (pri-miRNA) with a stem-loop structure. This is then endonucleolytically cleaved by the microprocessor complex of Drosha and DGCR8 to generate a~70 nt precursor hairpin miRNA (pre-miRNA) [12, 13] . Export of the premiRNA into the cytoplasm is facilitated by , where a complex consisting of Dicer and TRBP cleaves the pre-miRNA into a miRNA duplex (doublestranded). In vitro studies have suggested that both strands of the mature miRNA duplex are loaded into the RNA-induced-silencing complex (RISC). To induce translational repression of the target mRNA, one strand of this duplex must be degraded, possibly dependent on thermodynamic stabilities [15] . After strand selection, the RISC complex, which includes the core component Argonaute 2 [16] [17] [18] , guides the mature miRNA to an mRNA target, where the interaction promotes translational repression and target mRNA destabilizing through deadenylation (shortening of the 3 0 poly-A-tail) or cleavage of the mRNA target [19] [20] [21] [22] .
Function of microRNAs
miRNAs regulate gene expression in a sequence-specific manner [23] [24] [25] . The interaction between a miRNA and mRNA target mainly occurs through the seed region of the miRNA, which, for most miRNAs has been defined as nucleotides 2-8 from the 5 0 end of the sequence. This seed region interacts with a miRNA response element (MRE), often found in the 3 0 UTR of the mRNA target [25] .
However, the presence of an MRE in a target mRNA does not guarantee binding of a given miRNA, and many parameters such as mRNA secondary structure or sequence context of the site influence miRNA-mRNA interaction. miRNAs also interact through other regions of their sequence (noncanonical seed region) with the 3 0 UTR, and MREs can be found in the coding region, as well as the 5 0 UTR of the mRNA target [26, 27] . When examining all possible interactions between a miRNA and mRNA targets based on criteria limited to duplex energy, up to 10 000 or more putative target sites can be found per miRNA. However, most of these sites do not reflect actual miRNA binding, restricted to hundreds of sites per miRNA [28, 29] , with the additional complexity that each mRNA is potentially targeted by multiple miRNAs [30] . There are currently 2588 and 1915 human and mouse miRNAs, respectively, indexed in miRBase release 21 [31] . It is therefore not surprising that miRNAs are involved in the regulation of almost every cellular and developmental process, including the regulation of innate immune responses and inflammation, which need to be kept in check to avoid damage to the host [29] .
The role of miRNAs in innate immunity
The intracellular levels of different miRNAs are initially regulated at the transcriptional level by transcription factors dependent on the cell, tissue type, and environmental stimuli [32] . As such, innate immune responses directly regulate the expression of many miRNAs, which will be the main focus of this review.
The inflammatory response is characterized by coordinated activation of various signalling pathways that regulate expression of both pro-and anti-inflammatory mediators. The nuclear factor-jB (NF-jB) family of transcription factors is activated by and functions as a strong pro-inflammatory signal [33] , inducing the expression of proinflammatory genes including cytokines and chemokines [34] . NF-jB also regulates the transcription of many miRNAs including miR-146a, miR-155 and miR-21 [34-36], which come to regulate inflammation as a further feedback. Additionally, several post-transcriptional regulatory enzymes, influenced by inflammation and infection, have been identified to influence miRNA processing, such as ADAR1 and PNPT1, which are upregulated by innate immune responses and regulate pri-miRNA processing [32] or stability [37] . This feedback of miRNAs on innate immune pathways fine-tunes the responses to infection while helping to protect the host. Without this control, an inflammatory response may become chronic, resulting in tissue damage, and even cancer [38] . Figure 1 illustrates the complex effect of the miRNAs discussed in this review, focussing on TLR4 signalling. It is important to note that the effect of miRNAs on the translation of their targets is usually limited [39] , and that the capacity of miRNAs to functionally modulate pathways often relies on the convergence of their targeting at multiple levels of a given pathway (e.g. as seen with miR-19 which targets several negative regulators of NF-jB [40] ). In addition, several miRNAs can cooperate to regulate critical innate immune targets, across a broad range of cell types (see Table 1 for more examples of coregulated genes discussed in the review). Nonetheless this review is structured to focus on the roles of innate immune miRNAs rather than how innate immune genes are regulated by miRNAs (Table 2) .
Known miRNAs in innate immunity
Since their discovery, miRNAs have quickly become recognized as important modulators of inflammatory responses. Counter-intuitively, the activity of miRNAs is not limited to that of a simple 'brake' on inflammation. As such, we demonstrated that genetic disruption of miRNA biogenesis by deletion of Dicer1, globally depleting miRNA levels in macrophages, led to the decrease in inflammatory cytokines upon innate TLR4   IRAK1IRAK2   TRAF6   MYD88   TAB2 TAB3   TAK1  miR-155  miR-23b miR-23b, miR-26 [214] . Activation of MYD88 results in signal transduction (symbolized by the green arrows), ultimately promoting nuclear translocation of the NF-jB heterodimer (p50-p65), which binds to target NF-jB response elements in the genome to drive gene expression (e.g. pro-inflammatory mediators such as IL-6, IL-8, TNFa, or negative feedback regulators such as TNFAIP3). Proteins that act to dampen this canonical signalling are presented in red (e.g. TNFAIP3 [215] , SOCS1 [216] , SOCS3 [217] , ZBTB16 [218] ). Modulatory effects of miRNAs on positive and negative regulators of the pathway are indicated. See Table 2 for detailed references.
immune activation by several TLR ligands [40] . This indicates that several miRNAs are actually necessary to mount inflammatory responses. The following section will discuss the miRNAs that were first reported to modulate innate immunity, and their activities in different inflammatory contexts.
miR-146
miR-146a and -146b, found on chromosomes 5 and 10 in humans, respectively, are both upregulated follow- . miR-146b expression is controlled by STAT3, and is therefore up-regulated by IL-10 treatment of human monocytes [48] , while also dampening IL-6 production upon NF-jB activation [52] . Additionally, expression of miR-146a was found to be controlled by PU.1 and ApoE in mouse macrophages. ApoE-deficient macrophages released more TNFa and IL-6 after LPS stimulation compared to WT macrophages, concurrently with a reduction in miR-146a levels and an enhanced expression of IRAK1 and TRAF6 [53] . Importantly, rescue of ApoE expression enhanced miR-146a expression.
miR-155
miR-146a and miR-155 were the first miRNAs identified to be induced in immune cells stimulated by TLRs and proinflammatory cytokines [36] . In human and murine immune cells, miR-155 can be classified as an early response gene, since its expression is highly induced within 2 h of TLR activation (TLR2, TLR3, TLR4 and TLR9) [29] . miR-155 negatively regulates TLR-signalling by targeting key signalling molecules, including TAB2 [54] , MyD88 [55] , IKKe, RIPK1 [56] , C/EBPb [57] , eNOS [58] and NF-jB subunit p65 [58] (reviewed in more detail in [29] ). Overexpression of miR-155 suppresses production of the proinflammatory cytokines IL-8 and TNFa, whereas IL-10, which exerts anti-inflammatory properties, inhibits miR-155 expression [59] to maintain homeostasis. In this respect, it is interesting to note the opposing effects of IL-10 on both miR-155 and miR-146b, which execute different gene expression programs at different times after LPS stimulation. References are available in Table 2 . miR-155 also facilitates CXCL12 signalling through the inhibition of SHIP-1, a negative regulator of TLRinduced signals [60, 61] . Moreover, SHIP-1 regulation by miR-155 controls the pathogenesis of experimental colitis [62] , suggesting that miR-155 can also have proinflammatory functions. This is supported by the inhibition of SOCS1 by miR-155, which promoted inflammatory responses of macrophages and type-I IFN signalling [63] . Overall, miR-155 exerts both proand anti-inflammatory effects during innate immune activation.
miR-132
miR-132 is one of the few miRNAs initially identified as an upregulated miRNA in response to LPS in THP-1 macrophages [36] . It has been associated with proinflammatory activity, enhancing the release of IL-8 and MCP-1 in response to starvation, through SirT1 regulation in starved adipose-derived stem cells [64] . Conversely, miR-132 controls the levels of acetylcholinesterase (AChE) that normally degrades acetylcholine, and blunts its cholinergic anti-inflammatory activity in the periphery [65] [66] [67] [68] . Transgenic mice harbouring a modified AChE lacking the miR-132 target site had higher levels of proinflammatory cytokines and dysregulated body temperature, despite a robust miR-132 response, underlining the profound effect of miR-132 through AChE regulation [65] . These results were recapitulated using human inflammatory bowel disease (IBD) samples, indicating that miR-132 could be used as a biomarker for IBD and rheumatoid arthritis (RA) [69, 70] . However, it should be noted that other models have found no significant impact of miR-132 levels, probably relating to low basal expression of this miRNA [71] .
miR-21
miR-21 is one of the most abundantly expressed miRNA in many tissues, and is involved in many cellular processes [72, 73] . Activation of many immune cells with proinflammatory signals results in a further enhancement of miR-21 expression [73] [74] [75] [76] [77] [78] [79] . In keeping with its activation in immune cells, miR-21 is dysregulated in, but not limited to, cancer, psoriasis, allergic airway inflammation, osteoarthritis and heart disease [78, [80] [81] [82] [83] [84] [85] [86] [87] . Studies in macrophages indicate that miR-21 regulates PTEN, GSK3b and PDCD4, which collectively reduce the production of TNFa to LPS, while favouring IL-10 expression, indicating an antiinflammatory function of miR-21 [74, 88] . Further supporting this, miR-21 was found to target IL-12p35 in dendritic cells (DCs), suggesting that this miRNA protects the host from runaway inflammation [35, 89] . However, the role of miR-21 in inflammation is clearly context dependent since miR-21 knockout mice have lower proinflammatory cytokines and survive longer than controls using a colitis model [86] . Interestingly, miR-21 is also secreted into the circulation, making it a potential biomarker, and a potential TLR7 and TLR8 agonist [90] . Indeed, miR-21, along with miR-29a and miR-147, have been shown to act as TLR7 and 8 ligands, promoting the release of TNFa and IL-6 from macrophages. Given that miRNA inhibitors with 2 0 -Omethyl modification inhibit TLR7/8 [91, 92] , these have the capacity to exhibit dual activities on inflammation through steric miRNA sequestration and TLR7/8 inhibition [92] .
Let-7
The let-7 family of miRNAs, initially discovered in Caenorhabditis elegans (lin-4 was the first miRNA to be discovered), constitutes 12 variants, with three having a predominant function in innate immunity (let-7i, -7b and -7e). All three miRNAs target the 3 0 UTR of the TLR4 mRNA, leading to an overall decrease in LPS-induced inflammation [29, 93] . However, the effect of these three miRNAs on TLR4 is cell-type dependant, because let-7e is increased after TLR4 stimulation in peritoneal macrophages, whereas let-7i is decreased in bile-duct cholangiocytes [29] . Both let-7a and let-7b also target the proinflammatory cytokine IL-6 in hepatocarcinoma and in breast cancer cells, down-regulating tumour inflammation [94, 95] . Most recently, let-7b was found to inhibit keratinocyte migration, reducing wound healing [96] .
miR-223
miR-223 is another TLR-responsive miRNA, up-regulated by TLR9 through NF-jB binding of its promoter [97, 98] . This induction of miR-223 acts as a negative feedback loop, since miR-223 targets IKKa, thereby attenuating the TLR9/NF-jB signalling pathway in neutrophils [98] . Other miR-223 targets include granzyme B, Roquin and STAT3 [99] , as well as Pknox1, which all control inflammatory responses [100] . In addition, miR-223 also targets NLRP3, decreasing caspase-1 activation and subsequent processing of IL-1b [101] . However, loss of miR-223 in myeloid-derived cells in the intestines has been attributed to enhanced colitis in mouse models, due to destabilization of NLRP3 and the important role of IL-1b in gut homeostasis, indicating a much more involved role in miR-223 in IBD [102] . Circulating miR-223 levels were high in sera of RA patients, suggesting that miR-223 could function as a marker for RA disease activity [103, 104] .
miR-181b
miR-181b targets importin-a3, a protein required for nuclear translocation of NF-jB, and was found to be correlated with vascular inflammation in vascular epithelial cells [105] . Moreover, miR-181b directly targets the 3 0 UTR of the TNFa mRNA decreasing neuronal apoptosis and protecting neurons from cell death [106] . miR-181b is also induced by STAT3 and enhances NF-jB through control of CYLD expression, which normally acts as a brake on inflammation [107] . Conversely, miR-181a, another member of miR-181 family was found to target IL-1a in LPS-treated macrophages [108, 109] . All the members of the miR-181 family also favoured Hendra virus infection, through their targeting of ephrins (EphA5, EphA7 and EphB4), which block membrane fusions with henipaviruses in epithelial cells [110] .
miR-9
It is thought that miR-9 contributes to the return of homeostasis following immune activation through its targeting of NF-jB signalling, acting as a negative feedback mechanism. As such, miR-9 is induced by TLR2, TLR4, TLR7 and TLR8, and indirectly controls the production of proinflammatory cytokines [29] . Indeed, miR-9 is shown to directly target the mRNA of NFBK1 [46] , encoding for the p50 subunit of NF-jB. miR-9 additionally targets JAK1 and inhibits activation of the NLRP3 inflammasome in THP-1 derived macrophages [111] , collectively pointing to a predominantly anti-inflammatory activity. miR-9 also targets PTX3 to control phagocytosis of Staphylococcus aureus by macrophages [112] .
miR-147
miR-147 can be induced by NF-jB and STAT1a in a MYD88-and TRIF-dependent manner (i.e. it is induced by TLR2, TLR3 and TLR4) [113] . In a negative feedback loop following stimulation by the ligands for these TLRs, miR-147 decreases proinflammatory cytokine expression in macrophages. This suggests that miR-147 can act to decrease excessive cytokine production, however, the targets that influence this mechanism are currently unknown.
miR-17
The miR-17-92 cluster contains six separate miRNAs of four different families that are all cotranscribed, but their processing is individually regulated [114] . Initially named oncomiR-1 for its oncogenic properties [115] , this cluster has quickly become known for its immunomodulatory, developmental and metabolic roles too. It has two other paralogues on other chromosomes, the miR-106b-25 and miR-106a-363 clusters.
Nonetheless, the bulk of miR-17, 19 and 92 originates from the miR-17-92 cluster [116] .
miR-17, along with its family members miR-20a and miR-106a, were found to target SIRPa, which in turn enhanced macrophage inflammatory function [117] . By inhibiting these miRNAs in alveolar macrophages, phagocytosis was decreased and release of inflammatory signals TNFa, IL-6 and NO were all reduced [117] . Conversely, miR-17 directly targets IL-8, which has strong proinflammatory function in epithelial cells [118] , and suppresses TNFa signalling in RA by targeting TRAF2 and cIAP2 [119] .
miR-18
Overexpression of miR-18a targets Pias3 and TNFAIP3 (A20), which negatively regulate Stat3 and NF-jB signalling, respectively [120] . As such, overexpression of miR-18a in RASF cells, led to the potentiated induction of multiple inflammatory cytokines including IL-6, IL-8, MMP1, MCP1 and RANTES after TNFa stimulation [121] .
miR-19
miR-19a and -19b both share the same seed sequence [122] , and were initially found to target TNFa, suggesting that these miRNAs acted as anti-inflammatory miRNAs [123] . We and others have, however, later shown that miR-19a/b targets many negative regulators of NF-jB, including TNFAIP3, RNF11, KDM2A and ZBTB16, thus positively regulating inflammation in epithelial cells and T cells [40, [124] [125] [126] . miR-19 may also promote systemic inflammation by targeting ABCA1 in macrophages, decreasing serum highdensity lipoproteins and therefore enhancing atherosclerosis-driven inflammation too [127, 128] .
miR-301
Induced by NF-jB, miR-301 acts as a positive feedback mechanism by targeting NF-jB-repressing factor (NKRF) in pancreatic cancer cells [129] . This upregulation can also be seen in CD8 + T cells, where miR-301 targets CD69 [130] . miR-301 was also found to target PIAS3, an inhibitor of STAT3, favouring TH17 cell development and IL-17 production [131] .
miR-26
While controversy surrounds the ability of miR-26 to directly target IL-6 [132] [133] [134] , it appears that it can target several positive regulators of IL-6, including MALT1 and HMGA1 [133] . In addition, other inflammatory molecules including TNFa, IL-1a, IL-1b and Ccl5 were all upregulated following miR-26 mimic transfection, demonstrating that miR-26 exercises different effects on different pr-inflammatory signals [135] .
Novel miRNAs in innate immunity
Several miRNAs have been more recently linked to inflammation. These miRNAs and the context of their activities will be discussed in this section.
miR-23
The miR-23-27-24 cluster has recently been linked with innate immune responses. As such, miR-23a and -23b were found to target IKKa in primary chondrocytes, resulting in inhibition of IL-17 and decrease in IL-6, the chemokine MCP-1 and matrix metalloproteinase MMP-3 [136] . Similarly, miR-23b (but not -23a) suppressed IL-17-mediated TNFa production and the IL1b-induced NF-jB, through the targeting of TAB2, TAB3 and IKKa [137] . In a negative feedback loop, the NF-jB subunit p65 binds to the miR-23 promoter, inhibiting its expression [138] . In addition, transfection of miR-23b increases IL-10 in bone marrow-derived macrophages (BMDMs), while decreasing IL-12 production and enhancing T regulatory cells differentiation [139] .
miR-24
Overexpression of miR-24 inhibits cytokine secretion in response to TLR4 activation, due to targeting Class 1A PI 3-kinase subunit p110 delta (p110d) in primary human monocyte-derived macrophages [140] . Furthermore, miR-24 was found to target CHI3L1, thereby modulating S. aureus-induced macrophage polarization and increasing M2 anti-inflammatory factors such as Arg1, CCL17 and CCL22 [141, 142] . Conversely, miR-24 also attenuated phagocytosis of S. aureus and Escherichia coli while increasing the secretion of inflammatory cytokines TNFa, IL-6 and IL-12 [143] .
miR-27
miR-27 reduces the levels of TNFa, CXCL1 (KC) and CXCL2 (MIP-2) in LPS-stimulated lung tissue, suggesting a potential role for miR-27 in the negative regulation of proinflammatory cytokine production [80] . On the other hand, miR-27 targets MCPIP1, resulting in the increased secretion of proinflammatory cytokines IL-6 and IL-1b, as well as the anti-inflammatory cytokine IL-10 in LPS-stimulated RAW264.7 cells [144] .
miR-203
miR-203 targets several key signalling pathways following innate immune activation. In doing so, miR-203 targets the 3 0 UTR of the TLR adaptor protein MYD88 [145, 146] , and is highly induced in mice lung tissue following LPS stimulation [147] . miR-203 also directly targets TNFa, IL-24 and SOCS3 [81, 148] , suggesting an anti-inflammatory function.
miR-126
A recent study showed that miR-126 functions as a positive regulator of monocyte-mediated inflammatory responses by targeting CYLD in primary monocytes from chronic HIV-1 patients [149] . The proinflammatory role of miR-126 was further confirmed by its targeting of TOM1, a negative regulator of IL-1b and TNFa induced signalling pathways in cystic fibrosis (CF) airway epithelial cells, indicating that miR-126 plays an important role in regulating innate immune responses in CF patients [150] . In contradiction, miR-126 also directly targets CXCL12, a proinflammatory chemokine, thereby limiting atherosclerosis [151] . miR-126 also participates in the control of leucocyte trafficking during immune activation of the lung [152] , where it suppresses the effector function of Th2 cells in the airways [153, 154] .
miR-302
The miR-302 family, which consists of 5 members (miR-302a, b, c, d and e), was recently identified to regulate IFN responses in systemic lupus erythematosus (SLE) patients. SLE is a complex auto-immune disease targeting multiple organs, where up to 80% of SLE patients display an increased basal type-I IFN signature [155] . miR-302d targets IRF9, a critical component of the transcriptional complex regulating IFNstimulating genes (ISG), and was protective against hydrocarbon-induced lupus in mouse models [156] . Importantly, patients with increased ISG signatures have reduced expression of miR-302d [156] . miR-302b was also found to be induced by TLR2 and TLR4 through ERK-p38-NF-jB signalling upon Pseudomonas aeruginosa infection. In this context, it acts as a negative feedback loop on NF-jB, through targeting of IRAK4, resulting in increased survival of P. aeruginosa [157] .
miR-340
miR-340 targets JAK, and the STAT3 downstream signalling molecules BCL1, cyclin D1 and MMP2 in hepatocellular carcinoma (HCC) cells, ultimately down-regulating cytokine production, cell proliferation and invasion [158] . Furthermore, miR-340 directly targets the proinflammatory cytokine IL-4 [159] , thereby negatively influencing Th2 cell development and favouring a proinflammatory Th1 response in CD4 + T-cells from multiple sclerosis patients [160] .
miR-1246
miR-1246 is highly induced in LPS-stimulated pulmonary microvascular endothelial cells (PMVECs), contributing to apoptosis and promoting IL-1b and TNFa release [161] . miR-1246 also increases the levels of IL-6, CCL2 and CCL5 by targeting PRKAR1A and PPP2CB in mesenchymal stem/stroma cells [162] . Conversely, miR-1246 can also inhibit NF-jB signalling by targeting IGF2BP1 in lymphocytes [163] .
miR-34
miR-34 has three family members (miR-34a, b and c) with known functions in cancers, and recently their roles in innate immune responses has been elucidated. miR-34a targets a regulator of calcineurin RCAN1, which is an important regulator of inflammatory responses and endothelial inflammation in human umbilical vein endothelial cells (HUVECs) [164] . Moreover, miR-34a controls autophagy by targeting FoxOs in alveolar type II epithelial (AT-II) cells [165] . Excessive autophagic activity can cause acute liver injury (ALI), suggesting that miR-34a may have therapeutic value in this context [165] . miR-34a was induced by LPS, IL-1b, and TNFa in pancreatic b-cells [166] . Blocking miR-34a with an anti-miRNA-oligonucleotide protected MIN6 cells, a pancreatic b-cell line, from a cytokine-triggered cell death [166] .
miR-221 and miR-222
The cluster encoding both miR-221 and miR-222 was initially reported to be significantly increased following LPS stimulation in macrophages and human adipocytes, suggesting that NF-jB induces the expression of mature miR-221 and miR-222 expression [167] . This was later confirmed through the demonstration that both miRNAs are induced by NF-jB binding to their promoter [168] . Since both miRNAs share a common seed region, their activities have generally been considered as convergent. As such, miR-221 and miR-222 positively control NF-jB signalling through repression of negative regulators TNFAIP3 and SOCS1, as seen in colorectal cancer cells [89, [169] [170] [171] . STAT3 is also positively regulated by miR-221 and miR-222 [172, 173] , through their repression of SOCS1 [89, 171, 174] and SOCS3 [171, 175, 176] . A further target of miR-221 and miR-222 is IRF-2 [177] , a transcription factor which inhibits the activation of IFNa/b, thus enhancing type-I IFN signalling. Therefore, there is good evidence that miR-221 and miR-222 act as positive regulators of innate immune responses, however, further work is needed to confirm their direct involvement in disease context.
miR-320a
miR-320a, along with miR-221, were found to be upregulated in lung epithelial cells and released in microvesicles upon hypoxia treatment. Inhalation of these microvesicles resulted in greatly enhanced macrophage infiltration and migration, as well as enhanced cytokine release [178] . Using miRNA mimics of miR-320 enhanced the macrophage migration and expression of TNFa and MMP-9 in both THP-1 and BMDMs, although no target was validated in these studies [178] . Conversely, other studies have claimed that miR-320a targets NOD2 in IBD samples, and that its inhibition results in further NF-jB activation of cells [179] . Furthermore, there is a negative correlation between miR-320a expression and MMP-13, a known marker for ulcerative colitis [180] .
miR-674
Over-expression of miR-674 in bone marrow-derived DCs (BMDCs) increased the expression of IL-6, IL-12 and TNFa, inhibiting viral replication, and indicating that targets of miR-674 are likely inhibitors of antiviral responses. This effect has been attributed to the targeting of Mbnl3, Pgm2L1, Entpd6, Mbnl3, Camk1d and Aldh18a1 [181] . miR-674 may also be involved in liver inflammation although a detailed understanding of its activity remains elusive in this control [182] .
miR-33
miR-33 positively regulates inflammatory signalling through several modes of action. Mice fed with a high fat diet (HFD) for several weeks displayed decreased miR-33 levels in peritoneal macrophages, accompanied by an increase in RIP140 expression, a master regulator of transcription factors. Increase RIP140 levels were dependent on cholesterol and miR-33 levels [183] . Analysis of peritoneal macrophages from these mice also showed an elevated expression of TNFa and IL1b, with a heightened response to LPS. Critically, studies using miR-33 inhibitors indicated that cholesterol upregulation of RIP140 was miR-33 dependant [183] . In a separate study, LDLR À/À mice fed with a HFD while being treated with anti-miR-33 oligonucleotides halted progression of atherosclerosis. Inflammatory cytokines were altered in the aortas, with the levels of IL-1b and TNFa being increased, while those of IL-6 being decreased [184] . Further analysis using human aortic endothelial cells transfected with miR-33 anti-miRs indicated that the reduction in miR-33 had an anti-inflammatory effect through efflux of cholesterol [184] . Other studies confirmed the role of miR33a targeting the cholesterol efflux ABCA1 and ABCG1 [185] .
miR-10a
miR-10a has been found to be down-regulated in RA fibroblast-like synoviocytes (FLS), compared to osteoarthritis controls. Interestingly, miR-10a levels were reduced by TNFa and IL-1b stimulation [186] , suggesting a transcriptional repression of miR-10a during inflammation. This negative control of miR-10a was found to be dependent on YY1 binding to its promoter. Mimics of miR-10a reduced the expression of TNFa, IL-1b, MMP-1 and MMP-13 mRNA in FLS, while also reducing both IL-6 and IL-18 cytokine release. This anti-inflammatory effect of miR-10a was attributed to the targeting of IRAK4, TAK1 and BTRC [186] . As such, these findings suggest that miR10a mimics may have therapeutic value for RA patients.
miR-145
miR-145 targets the Toll-interleukin-1 receptor domain-containing adaptor protein (TIRAP, or MAL), thereby inhibiting TLR4 signalling [187] . miR-145 levels were found to be induced in the airway of mice sensitized to dust mite, along with these of miR-21 and let-7b [188] . Treatment with miRNA inhibitors reduced the number of mucus producing cells and eosinophils in the airways, while also reducing IL-5 and IL-13 production from Th2 cells [188] . miR-145 has also been linked to TNFa production, through its effect on ADAM17 which is essential for the cleavage of TNFa into its secreted and membrane bound forms [189] . However, an independent report relying on overexpression of miR-145 indicated that while decreasing ADAM17, miR-145 enhanced p65 nuclear translocation and production of TNFa in human adipose tissue, although the detailed mechanism of action remains unknown [190] . Finally, miR-145 has been proposed to facilitate the anti-inflammatory function of aspirin in vascular smooth muscle through its effect on IL-6 [191] .
microRNA isoforms in innate immune responses
As introduced previously, the processing and stability of miRNAs can be impacted by innate immune regulated proteins such as ADAR1 or PNPT1 [32, 37] . While controlling miRNA levels, regulation of Dicer and Drosha processing can also affect the final sequence of a mature miRNA, by impacting the 3 0 and 5 0 ends. Initially dismissed by the scientific community, there is now overwhelming evidence that such miRNA end-variations are very frequent [192] , and impact miRNA function [193, 194] . These variations of precursor processing lead to the generation of 'templated isoforms', or 'isomiRs', which are more common at the 3 0 end of the miRNA [195] . While studying the impact of type-I IFN responses on miRNA isoforms in human fibroblasts, we discovered a length-specific decrease in a few select 3 0 -miRNA isoforms, with the example of miR-221-3p and miR-222-3p [196] . The longer variants of these miRNAs were selectively decreased, while their shorter counterparts were increased. PNPT1 was involved in the length-specific decrease in miR-221-3p and miR-222-3p in melanoma MeWo cells, but other factors were likely involved [196] .
Critically, in addition to impacting the abundance of certain miRNA families, such isoform selective effects can lead to misinterpretation of results upon innate immune activation involving type-I IFN. We discovered that Taqman stem-loop and polyadenylationbased reverse transcription quantitative real-time polymerase chain reaction (RT-qPCR) detection of miRNAs could introduce a strong bias towards certain 3 0 -isoforms, particularly important when the assays were designed against longer variants (> 22 nt) -for instance leading to the identification of induced miR-222-3p by TLR4, when the most abundant isoform of this miRNA was in fact decreased [196, 197] . In addition, small RNA sequencing of monocyte-derived DCs infected by bacteria demonstrated global changes in miRNA isoforms [196] , illustrating further the importance of miRNA length variations in innate immunity.
While strategies can be devised to confer increased specificity to select isoforms [197] , these studies suggest that RT-qPCR detection of miRNAs modulated by innate immunity should be used with caution, since it may lead to misinterpretation of results.
Conclusion
As illustrated in this comprehensive (but not exhaustive) review, most miRNAs implicated in the modulation of inflammation can in fact exhibit both pro and anti-inflammatory activities. In addition, we note that miRNAs that display either pro or anti-inflammatory functions have often been recently discovered, or are not as well defined in the literature as other more agnostic miRNAs. miRNAs regulate complex networks of genes, and it is therefore not surprising that opposite phenotypes can be observed for a same miRNA. Nonetheless, it should be underlined that most of the studies published in the field to date rely on a gene-centric approach, where one miRNA regulates (a) key inflammatory gene(s). In normal conditions, inflammation aims at rapidly protecting the host, while safeguarding a prompt return to homeostasis. This is achieved through the induction of both pro and anti-inflammatory mediators, which are very dynamically regulated. However, the levels of the miRNAs induced by innate immunity (e.g. miR-146, miR-155, miR-21), are generally very stable [198] and therefore commit the cell into a specific state it cannot easily revert from. During the course of the inflammatory response, induced miRNAs will therefore target different functions, either pro or anti-inflammatory, depending on the targets expressed. This underlines the context-dependent effect of miRNAs, with opposite action on the immune system in tissues expressing different targets. Such impact of the cellular context on the outcome of the miRNA regulation presents important risks for the use of miRNA therapeutics (mimics or inhibitors), with adjacent/nontargeted tissue potentially compromising the overall outcome. Importantly, since innate immune responses can feed back to modulate the stability of longer isoforms [196] , and that isoform stoichiometry can vary substantially between tissues [192] , it is likely that isoform-specific functions may also explain the different outcomes on immune responses seen in different tissues.
One of the most interesting aspects of miRNA regulation of protein translation, is that it is rarely greater than 2 fold [39] . Yet, miRNAs have robust effects on signalling pathways and inflammation as described in this review. This relates to the convergent activity of the targets coregulated by individual miRNAs, within specific pathways. As such, and as evidenced with miR-146b, miRNAs often regulate signalling pathways at various levels (e.g. TLR4, MyD88, IRAK1, TRAF6 for miR-146b), which add up to a strong biological outcome. This convergent regulation is likely to be the result of evolutionary pressure, but may present unique opportunities to identify novel components of signalling pathways involved in inflammation, similar to genes that are coregulated by transcription factors. Critically, further studies should focus on pathway regulation by miRNAs rather than individual targets, to elucidate differences in miRNA function between cellular contexts where these signalling pathways differ.
As a conclusion, our broad review of the field confirms that miRNAs play a critical role in the modulation of innate immune responses and inflammation. With accumulating miRNA therapeutics now being tested in human clinical trials, it is becoming clear that modulation of miRNA function could soon present novel therapeutic avenues to treat auto-inflammation and auto-immunity [199] . Nonetheless, further efforts in the field should focus on the more global (and less context-dependent) definition of miRNA activities, to facilitate the identification of the most promising miRNA candidates for the clinical modulation of aberrant inflammation. In addition, with the greater affordability of small RNA sequencing studies, it will be important to refine our understanding of their regulatory function at the isoform level, thereby potentially leading to the identification of disease-specific isoforms to be used as biomarkers [192] .
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